Doxycycline hyclate

TQ05310 was provided by Jiangsu Chia‐Tai Tianqing Pharmaceutical Co., Ltd (Nanjing, China). AG‐221 and doxycycline hyclate were purchased from Selleckchem (Boston, MA, USA). Monoclonal antibodies against IDH1 and Myc‐tag were purchased from Cell Signaling Technology (Danvers, MA, USA). Monoclonal antibodies against IDH2, IDH2‐R172K,20 and GAPDH were purchased from Abcam (Cambridge, UK), MBL International Corporation (Woburn, MA, USA) and AbSci (College Park, MD, USA), respectively. rhEPO was obtained from 3SBio Inc. (Shenyang, China). dl‐Isocitric acid trisodium salt hydrate was purchased from Sigma‐Aldrich (St Louis, MO, USA).

Doxycycline hyclate, minocycline HCl and tigecycline were obtained from Selleck Chemicals, Houston, TX, USA. EtOH (200 proof, Decon Labs, King of Prussia, PA, USA) was used in all experiments. For some studies, saccharin sodium salt hydrate (Sigma-Aldrich, St. Louis, MO, USA) was used. Vehicle for all drugs was physiological saline and drugs were given by intraperitoneal injection (ip) in a volume of 10 ​ml/kg body weight.